Cough Science News
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
This month’s roundup explores placebo effects in RCC trials, the role of interoception in chronic cough, and the cost burden of persistent symptoms, plus insights from Dr. Nadia Giannetti.
New key cough science publications, Actigraph x Hyfe partnership and more
This year marked significant progress in cough monitoring, solidifying cough as a valuable biomarker in diverse therapeutic areas
New findings on refractory chronic cough (RCC), pulmonary tuberculosis, and pulmonary fibrosis. Plus latest white papers by Hyfe.
Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies
Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies
Cough Science News, August 2024 - Explore studies on cough variability, acute cough duration, and the cost burden of chronic cough. Plus, discover the world’s most comprehensive collection of cinematic coughs and upcoming events in cough science
CougH Science News July 2024 - latest in cough science. Insights on cough detection algorithms, pulmonary fibrosis, asthma diagnosis from cough sounds, and more. Plus, watch expert discussions and stay updated on upcoming events
Hyfe Cough Science News, June 2024. Latest research on cough in fibrotic ILD, high-dose inhaled corticosteroids for chronic cough, and family physicians’ approaches to managing chronic cough. Plus, insights from leading researchers and upcoming events
Cough Science News May 2024 - studies on cough monitoring for COVID-19 surveillance, the effectiveness of codeine for chronic cough, factors in refractory cough in IPF, and more. Plus, insights from researchers and upcoming events
Hyfe Cough Science News, March 2024 - insights on chronic cough management in the UK, common triggers in cough hypersensitivity, and a review of treatments for refractory cough. Plus, expert Q&A and upcoming cough science events.
Key Takeaway: Up to 50% of patients presenting with cough continue to have unexplained cough even after thorough investigation. The authors of this paper argue that in these cases cough should be treated as a disease in its own right. Many patients have cough hypersensitivity and impaired cough suppressibility, characteristics associated with measurable alterations in specific areas of the brain.
Why It Matters: Whilst the concept of chronic cough as a standalone disease is gaining ground, many healthcare practitioners still treat cough as a symptom of a comorbid condition. This results in exhaustive - expensive and burdensome - testing to exclude diseases. Many patients remain frustrated and this paper proposes an alternative approach.
Key Takeaway: A review of 286 patient in the Korean Severe Asthma Registry showed that those with chronic cough had poorer asthma control and worse quality-of-life than those without. During follow-up, patients with chronic cough experienced more exacerbations (48.3% vs. 28.6%) than those without chronic cough.
Why It Matters: This study adds to the growing body of evidence that chronic cough is an important signifier of poor asthma control, and that its management could improve quality of life.
Key Takeaways: This study of 23 problematic coughers compared cough frequency data collected by the Hyfe cough monitoring software with continuous audio labeled according to a published and validated SOP. A total of 546 hours of continuous audio/monitoring time containing 4,454 cough seconds was captured from all participants with multiple etiologies. The overall sensitivity of Hyfe’s cough-monitoring software was 90.4% (95% CI of 88.3–92.2%). The overall false positive rate was 1.03 false positives per hour (95% CI of 0.84 to 1.24).
Why it matters: There is increasing recognition that cough is highly variable day-to-day and therefore long-term continuous monitoring is critical to evaluate baseline and understand cough trends. The accuracy of Hyfe’s cough-monitoring software using only a wrist-worn watch mic, is one example of a cough monitor that combines high validity with high patient acceptability for long periods of time.
This month Hyfe announced an exciting partnership with Actigraph, the leader in wearable technology for collecting digital measures in clinical trials. We spoke with Christine Guo to get the lowdown on the collaboration and the novel opportunities for research now that Hyfe’s cough-monitoring software is integrated into Actigraph’s flagship product.
